Limited Capability for Testing <i>Mycobacterium tuberculosis</i> for Susceptibility to New Drugs

Hamzah Z. Farooq, Daniela María Cirillo, Doris Hillemann, David Wyllie, Marieke J. van der Werf, Csaba Ködmön, Vladyslav Nikolayevskyy

Emerging infectious diseases · 2021 · 20 citations · 6 references

DOIFull text

Open access

Concepts

Abstract

We surveyed availability of phenotypic drug susceptibility testing for drug-resistant Mycobacterium tuberculosis in Europe. Of 27 laboratories, 17 tested for linezolid, 11 for clofazimine, 9 for bedaquiline, and 6 for delamanid during 2019. Our findings indicate that testing capacity for newer and repurposed tuberculosis drugs exists, but its availability is limited.

References

6